N2-(4-(dimethylamino)phenyl)-4′-methyl-[4,5′-bithiazole]-2,2′-diamine | 315705-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N2-(4-(dimethylamino)phenyl)-4′-methyl-[4,5′-bithiazole]-2,2′-diamine
• 英文别名: 1-N-[4-(2-amino-4-methyl-1,3-thiazol-5-yl)-1,3-thiazol-2-yl]-4-N,4-N-dimethylbenzene-1,4-diamine
• CAS: 315705-02-3
• 化学式: C₁₅H₁₇N₅S₂
• 分子量: 331.465
• InChiKey: AXLQBSBVVDAWDD-UHFFFAOYSA-N

物化性质

• 沸点：
  551.2±60.0 °C(predicted)
• 密度：
  1.365±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N2-(4-(dimethylamino)phenyl)-4′-methyl-[4,5′-bithiazole]-2,2′-diamine 、 丙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以68%的产率得到N-(2-((4-(dimethylamino)phenyl)amino)-4′-methyl-[4,5′-bithiazol]-2′-yl)propionamide
  参考文献：
  名称：

  Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases

  摘要：

  Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90% of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.

  DOI：

  10.1021/acs.jmedchem.6b01521
• 作为产物：
  描述：

  5-乙酰基-2-氨基-4-甲基噻唑 在 氢溴酸 、 溴 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 3.5h， 生成 N2-(4-(dimethylamino)phenyl)-4′-methyl-[4,5′-bithiazole]-2,2′-diamine
  参考文献：
  名称：

  Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases

  摘要：

  Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90% of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.

  DOI：

  10.1021/acs.jmedchem.6b01521

文献信息

• Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases
  作者：Sabrina Tassini、Liang Sun、Kristina Lanko、Emmanuele Crespan、Emily Langron、Federico Falchi、Miroslava Kissova、Jorge I. Armijos-Rivera、Leen Delang、Carmen Mirabelli、Johan Neyts、Marco Pieroni、Andrea Cavalli、Gabriele Costantino、Giovanni Maga、Paola Vergani、Pieter Leyssen、Marco Radi

  DOI：10.1021/acs.jmedchem.6b01521

  日期：2017.2.23

  Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90% of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.